Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Archives of Dermatological Research
Published in: Archives of Dermatological Research 1/2017

01-01-2017 | Original Paper

CD164 identifies CD4+ T cells highly expressing genes associated with malignancy in Sézary syndrome: the Sézary signature genes, FCRL3, Tox, and miR-214

Authors: Bernice M. Benoit, Neha Jariwala, Geraldine O’Connor, Landon K. Oetjen, Timothy M. Whelan, Adrienne Werth, Andrea B. Troxel, Hélène Sicard, Lisa Zhu, Christopher Miller, Junko Takeshita, Daniel W. McVicar, Brian S. Kim, Alain H. Rook, Maria Wysocka

Published in: Archives of Dermatological Research | Issue 1/2017

Login to get access

Abstract

Sézary syndrome (SS), a leukemic variant of cutaneous T-cell lymphoma (CTCL), is associated with a significantly shorter life expectancy compared to skin-restricted mycosis fungoides. Early diagnosis of SS is, therefore, key to achieving enhanced therapeutic responses. However, the lack of a biomarker(s) highly specific for malignant CD4+ T cells in SS patients has been a serious obstacle in making an early diagnosis. We recently demonstrated the high expression of CD164 on CD4+ T cells from Sézary syndrome patients with a wide range of circulating tumor burdens. To further characterize CD164 as a potential biomarker for malignant CD4+ T cells, CD164+ and CD164−CD4+ T cells isolated from patients with high-circulating tumor burden, B2 stage, and medium/low tumor burden, B1–B0 stage, were assessed for the expression of genes reported to differentiate SS from normal controls, and associated with malignancy and poor prognosis. The expression of Sézary signature genes: T plastin, GATA-3, along with FCRL3, Tox, and miR-214, was significantly higher, whereas STAT-4 was lower, in CD164+ compared with CD164−CD4+ T cells. While Tox was highly expressed in both B2 and B1–B0 patients, the expression of Sézary signature genes, FCRL3, and miR-214 was associated predominantly with advanced B2 disease. High expression of CD164 mRNA and protein was also detected in skin from CTCL patients. CD164 was co-expressed with KIR3DL2 on circulating CD4+ T cells from high tumor burden SS patients, further providing strong support for CD164 as a disease relevant surface biomarker.
Literature
1.
2.
Aliahmad P, Seksenyan A, Kaye J (2012) The many roles of TOX in the immune system. Curr Opin Immunol 24:173–177CrossRefPubMed
3.
Ballabio E, Mitchell T, van Kester MS, Taylor S, Dunlop HM, Chi J, Tosi I, Vermeer MH, Tramonti D, Saunders NJ et al (2010) MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential. Blood 116:1105–1113CrossRefPubMedPubMedCentral
4.
Begue E, Jean-Louis F, Bagot M, Jauliac S, Cayuela JM, Laroche L, Parquet N, Bachelez H, Bensussan A, Courtois G et al (2012) Inducible expression and pathophysiologic functions of T-plastin in cutaneous T-cell lymphoma. Blood 120:143–154CrossRefPubMed
5.
Bensussan A, Remtoula N, Sivori S, Bagot M, Moretta A, Marie-Cardine A (2011) Expression and function of the natural cytotoxicity receptor NKp46 on circulating malignant CD4+ T lymphocytes of Sezary syndrome patients. J Invest Dermatol 131:969–976CrossRefPubMed
6.
Boonk SE, Cetinozman F, Vermeer MH, Jansen PM, Willemze R (2015) Differential expression of TOX by skin-infiltrating T cells in Sezary syndrome and erythrodermic dermatitis. J Cutan Pathol 42:604–609CrossRefPubMed
7.
Campbell JJ, Clark RA, Watanabe R, Kupper TS (2010) Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood 116:767–771CrossRefPubMedPubMedCentral
8.
Chung JS, Dougherty I, Cruz PD Jr, Ariizumi K (2007) Syndecan-4 mediates the coinhibitory function of DC-HIL on T cell activation. J Immunol 179:5778–5784CrossRefPubMed
9.
Chung JS, Shiue LH, Duvic M, Pandya A, Cruz PD Jr, Ariizumi K (2011) Sezary syndrome cells overexpress syndecan-4 bearing distinct heparan sulfate moieties that suppress T-cell activation by binding DC-HIL and trapping TGF-beta on the cell surface. Blood 117:3382–3390CrossRefPubMedPubMedCentral
10.
Coustan-Smith E, Song G, Clark C, Key L, Liu P, Mehrpooya M, Stow P, Su X, Shurtleff S, Pui CH et al (2011) New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood 117:6267–6276CrossRefPubMedPubMedCentral
11.
12.
Ferenczi K, Fuhlbrigge RC, Pinkus J, Pinkus GS, Kupper TS (2002) Increased CCR4 expression in cutaneous T cell lymphoma. J Invest Dermatol 119:1405–1410CrossRefPubMed
13.
Goswami M, Duvic M, Dougherty A, Ni X (2012) Increased Twist expression in advanced stage of mycosis fungoides and Sezary syndrome. J Cutan Pathol 39:500–507CrossRefPubMedPubMedCentral
14.
Guenova E, Ignatova D, Chang YT, Contassot E, Mehra T, Saulite I, Navarini AA, Mitev V, Dummer R, Kazakov DV et al (2015) Expression of CD164 on malignant T cells in Sezary syndrome. Acta Derm Venereol 96:464–467CrossRef
15.
Guenova E, Watanabe R, Teague JE, Desimone JA, Jiang Y, Dowlatshahi M, Schlapbach C, Schaekel K, Rook AH, Tawa M et al (2013) TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma. Clin Cancer Res 19:3755–3763CrossRefPubMedPubMedCentral
16.
Havens AM, Jung Y, Sun YX, Wang J, Shah RB, Buhring HJ, Pienta KJ, Taichman RS (2006) The role of sialomucin CD164 (MGC-24v or endolyn) in prostate cancer metastasis. BMC Cancer 6:195–207CrossRefPubMedPubMedCentral
17.
Huang AF, Chen MW, Huang SM, Kao CL, Lai HC, Chan JY (2013) CD164 regulates the tumorigenesis of ovarian surface epithelial cells through the SDF-1alpha/CXCR4 axis. Mol Cancer 12:115–127CrossRefPubMedPubMedCentral
18.
Huang Y, Su MW, Jiang X, Zhou Y (2015) Evidence of an oncogenic role of aberrant TOX activation in cutaneous T-cell lymphoma. Blood 125:1435–1443CrossRefPubMed
19.
Jain S, Stroopinsky D, Yin L, Rosenblatt J, Alam M, Bhargava P, Clark RA, Kupper TS, Palmer K, Coll MD et al (2015) Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma. Blood 126:354–362CrossRefPubMedPubMedCentral
20.
Jindra PT, Bagley J, Godwin JG, Iacomini J (2010) Costimulation-dependent expression of microRNA-214 increases the ability of T cells to proliferate by targeting Pten. J Immunol 185:990–997CrossRefPubMedPubMedCentral
21.
Kari L, Loboda A, Nebozhyn M, Rook AH, Vonderheid EC, Nichols C, Virok D, Chang C, Horng WH, Johnston J et al (2003) Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma. J Exp Med 197:1477–1488CrossRefPubMedPubMedCentral
22.
Kim BS, Siracusa MC, Saenz SA, Noti M, Monticelli LA, Sonnenberg GF, Hepworth MR, Van Voorhees AS, Comeau MR, Artis D (2013) TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation. Sci Transl Med 5:170ra116CrossRef
23.
Kim EJ, Hess S, Richardson SK, Newton S, Showe LC, Benoit BM, Ubriani R, Vittorio CC, Junkins-Hopkins JM, Wysocka M et al (2005) Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 115:798–812CrossRefPubMedPubMedCentral
24.
Leccia F, Nardone A, Corvigno S, Vecchio LD, De Placido S, Salvatore F, Veneziani BM (2012) Cytometric and biochemical characterization of human breast cancer cells reveals heterogeneous myoepithelial phenotypes. Cytometry A 81:960–972CrossRefPubMed
25.
Litvinov IV, Netchiporouk E, Cordeiro B, Zargham H, Pehr K, Gilbert M, Zhou Y, Moreau L, Woetmann A, Odum N et al (2014) Ectopic expression of embryonic stem cell and other developmental genes in cutaneous T-cell lymphoma. Oncoimmunology 3:e970025-970021-970028CrossRef
26.
Matsui T, Kurosawa N, Hibi K, Akiyama S, Kasai Y, Sakamoto J, Ito K, Nakao A, Muramatsu T (2000) The ratio of splicing variants of MGC-24/CD164, a sialomucin, correlates with the metastatic potential of colorectal carcinomas. J Biochem 127:1103–1107CrossRefPubMed
27.
Merritt WD, Taylor BJ, Der-Minassian V, Reaman GH (1996) Coexpression of GD3 ganglioside with CD45RO in resting and activated human T lymphocytes. Cell Immunol 173:131–148CrossRefPubMed
28.
Moins-Teisserenc H, Daubord M, Clave E, Douay C, Felix J, Marie-Cardine A, Ram-Wolff C, Maki G, Beldjord K, Homyrda L et al (2015) CD158k is a reliable marker for diagnosis of Sezary syndrome and reveals an unprecedented heterogeneity of circulating malignant cells. J Invest Dermatol 135:247–257CrossRefPubMed
29.
Morimura S, Sugaya M, Suga H, Miyagaki T, Ohmatsu H, Fujita H, Asano Y, Tada Y, Kadono T, Sato S (2014) TOX expression in different subtypes of cutaneous lymphoma. Arch Dermatol Res 306:843–849CrossRefPubMed
30.
Murphy GF (1988) Cutaneous T-cell lymphoma. Adv Pathol 1:131–156
31.
Nagata S, Ise T, Pastan I (2009) Fc receptor-like 3 protein expressed on IL-2 nonresponsive subset of human regulatory T cells. J Immunol 182:7518–7526CrossRefPubMedPubMedCentral
32.
Narducci MG, Arcelli D, Picchio MC, Lazzeri C, Pagani E, Sampogna F, Scala E, Fadda P, Cristofoletti C, Facchiano A et al (2011) MicroRNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in Sezary syndrome. Cell Death Dis 2:e151CrossRefPubMedPubMedCentral
33.
Nebozhyn M, Loboda A, Kari L, Rook AH, Vonderheid EC, Lessin S, Berger C, Edelson R, Nichols C, Yousef M et al (2006) Quantitative PCR on 5 genes reliably identifies CTCL patients with 5 to 99 % circulating tumor cells with 90 % accuracy. Blood 107:3189–3196CrossRefPubMedPubMedCentral
34.
Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, Wood GS, Willemze R, Demierre MF, Pimpinelli N et al (2011) Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 29:2598–2607CrossRefPubMedPubMedCentral
35.
Penna E, Orso F, Taverna D (2014) miR-214 as a key hub that controls cancer networks: small player, multiple functions. J Invest Dermatol 135:960–969CrossRefPubMed
36.
Poszepczynska-Guigne E, Schiavon V, D’Incan M, Echchakir H, Musette P, Ortonne N, Boumsell L, Moretta A, Bensussan A, Bagot M (2004) CD158k/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sezary syndrome. J Invest Dermatol 122:820–823CrossRefPubMed
37.
Scala E, Abeni D, Pomponi D, Narducci MG, Lombardo GA, Mari A, Frontani M, Picchio MC, Pilla MA, Caprini E et al (2010) The role of 9-O-acetylated ganglioside D3 (CD60) and {alpha}4{beta}1 (CD49d) expression in predicting the survival of patients with Sezary syndrome. Haematologica 95:1905–1912CrossRefPubMedPubMedCentral
38.
Showe LC, Fox FE, Williams D, Au K, Niu Z, Rook AH (1999) Depressed IL-12-mediated signal transduction in T cells from patients with Sezary syndrome is associated with the absence of IL-12 receptor beta 2 mRNA and highly reduced levels of STAT4. J Immunol 163:4073–4079PubMed
39.
Sokolowska-Wojdylo M, Wenzel J, Gaffal E, Steitz J, Roszkiewicz J, Bieber T, Tuting T (2005) Absence of CD26 expression on skin-homing CLA+ CD4+ T lymphocytes in peripheral blood is a highly sensitive marker for early diagnosis and therapeutic monitoring of patients with Sezary syndrome. Clin Exp Dermatol 30:702–706CrossRefPubMed
40.
Tang J, Zhang L, She X, Zhou G, Yu F, Xiang J, Li G (2012) Inhibiting CD164 expression in colon cancer cell line HCT116 leads to reduced cancer cell proliferation, mobility, and metastasis in vitro and in vivo. Cancer Invest 30:380–389CrossRefPubMed
41.
van Doorn R, Dijkman R, Vermeer MH, Out-Luiting JJ, van der Raaij-Helmer EM, Willemze R, Tensen CP (2004) Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sezary syndrome identified by gene expression analysis. Cancer Res 64:5578–558642CrossRefPubMed
42.
Watt SM, Butler LH, Tavian M, Buhring HJ, Rappold I, Simmons PJ, Zannettino AC, Buck D, Fuchs A, Doyonnas R et al (2000) Functionally defined CD164 epitopes are expressed on CD34(+) cells throughout ontogeny but display distinct distribution patterns in adult hematopoietic and nonhematopoietic tissues. Blood 95:3113–3124PubMed
43.
Wysocka M, Kossenkov AV, Benoit BM, Troxel AB, Singer E, Schaffer A, Kim B, Dentchev T, Nagata S, Ise T et al (2014) CD164 and FCRL3 are highly expressed on CD4+ CD26- T cells in Sezary syndrome patients. J Invest Dermatol 134:229–236CrossRefPubMed
44.
Yawalkar N, Ferenczi K, Jones DA, Yamanaka K, Suh KY, Sadat S, Kupper TS (2003) Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma. Blood 102:4059–4066CrossRefPubMed
45.
Yin G, Chen R, Alvero AB, Fu HH, Holmberg J, Glackin C, Rutherford T, Mor G (2010) TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214. Oncogene 29:3545–3553CrossRefPubMedPubMedCentral
Metadata
Title
CD164 identifies CD4+ T cells highly expressing genes associated with malignancy in Sézary syndrome: the Sézary signature genes, FCRL3, Tox, and miR-214
Authors
Bernice M. Benoit
Neha Jariwala
Geraldine O’Connor
Landon K. Oetjen
Timothy M. Whelan
Adrienne Werth
Andrea B. Troxel
Hélène Sicard
Lisa Zhu
Christopher Miller
Junko Takeshita
Daniel W. McVicar
Brian S. Kim
Alain H. Rook
Maria Wysocka
Publication date
01-01-2017
Publisher
Springer Berlin Heidelberg
Published in
Archives of Dermatological Research / Issue 1/2017
Print ISSN: 0340-3696
Electronic ISSN: 1432-069X
DOI
https://doi.org/10.1007/s00403-016-1698-8

Other articles of this Issue 1/2017

Archives of Dermatological Research 1/2017 Go to the issue

Original Paper

Ketoconazole inhibits Malassezia furfur morphogenesis in vitro under filamentation optimized conditions

Original Paper

Epidermal hydrogen peroxide is not increased in lesional and non-lesional skin of vitiligo

Original Paper

3D modeling of keloid scars in vitro by cell and tissue engineering

Original Paper

Cytokeratin AE1/AE3 immunostaining and 3D-histology: improvement of diagnosis in desmoplastic squamous cell carcinoma of the skin

Original Paper

Histopathological and immunological changes during the acute and recovery phase in Henoch–Schönlein purpura rabbit model

Concise Communication

Methyl-β-cyclodextrin treatment combined to incubation with interleukin-4 reproduces major features of atopic dermatitis in a 3D-culture model